Our Pricing

Complete Mounjaro Dosage Chart: UK Prescribing Guide

Published on: June 03, 2026

Understanding the mounjaro dosage chart is essential for safe and effective weight loss treatment with tirzepatide. This comprehensive guide provides a structured breakdown of Mounjaro's dose escalation schedule, from the initial 2.5mg starting dose through to the maximum 15mg maintenance dose, helping patients and prescribers navigate the treatment pathway with confidence.

Understanding the Mounjaro Dosage Chart Structure

The mounjaro dosage chart follows a carefully designed escalation protocol developed through the SURPASS clinical trial programme [1]. Treatment begins with a subcutaneous injection of 2.5mg once weekly for four weeks, serving as an initiation dose to help the body adjust to tirzepatide whilst minimising gastrointestinal side effects. This starting phase is not intended for glycaemic control or weight loss but rather to build tolerance.

After the initial four-week period, the dose increases to 5mg weekly, which represents the first therapeutic dose. Patients typically remain at each dose level for at least four weeks before escalation, allowing clinical assessment of tolerability and response. The structured progression continues through 7.5mg, 10mg, 12.5mg, and finally 15mg as the maximum maintenance dose [2]. At Cured Pharmacy, Mounjaro is available from £124.99 following online clinical assessment by our UK-registered prescribers.

Each dose escalation should be guided by individual patient response, tolerability, and clinical goals. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that not all patients require progression to the maximum dose—many achieve their target weight loss at intermediate doses. The mounjaro dosage chart provides a framework, but treatment remains personalised based on ongoing clinical evaluation.

Mounjaro Dosage Chart: Week-by-Week Breakdown

The standard mounjaro dosage chart progression follows this schedule: Weeks 1-4 use 2.5mg (yellow pen cap), Weeks 5-8 use 5mg (grey pen cap), Weeks 9-12 use 7.5mg (blue pen cap), Weeks 13-16 use 10mg (orange pen cap), Weeks 17-20 use 12.5mg (purple pen cap), and Week 21 onwards may use 15mg (brown pen cap) if clinically appropriate [3].

Each KwikPen contains four pre-filled doses of the same strength, administered subcutaneously once weekly on the same day each week. The colour-coded pen system helps prevent dosing errors and ensures patients can easily identify their current dose level. Injection sites should be rotated between the abdomen, thigh, or upper arm to reduce injection site reactions.

Clinical trials demonstrated that gradual dose escalation according to this mounjaro dosage chart significantly reduced the incidence of gastrointestinal adverse events compared to more rapid titration schedules [1]. Patients should not skip doses or accelerate the schedule without prescriber guidance, as this may compromise both safety and efficacy.

Adjusting Your Mounjaro Dose Schedule

While the standard mounjaro dosage chart provides clear guidance, individual circumstances may require schedule modifications. If a patient experiences persistent nausea, vomiting, or diarrhoea, the prescriber may recommend remaining at the current dose for an additional four weeks before escalation. Conversely, if weight loss plateaus at a lower dose and tolerability is excellent, earlier progression may be considered.

Missed doses should be administered as soon as possible if within four days of the scheduled injection. If more than four days have passed, skip the missed dose and resume the regular schedule. After extended treatment interruptions exceeding 21 days, reinitiation at the 2.5mg dose is typically recommended to re-establish tolerance, following the mounjaro dosage chart from the beginning.

Clinical Evidence Behind the Mounjaro Dosage Chart

The mounjaro dosage chart escalation protocol is grounded in robust clinical trial data from the SURMOUNT programme, specifically designed to evaluate tirzepatide for chronic weight management [4]. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus weight-related comorbidities, demonstrating that the gradual dose escalation schedule optimised both efficacy and tolerability.

Results showed that participants following the structured mounjaro dosage chart achieved average weight reductions of 15.0% with the 5mg dose, 19.5% with the 10mg dose, and 20.9% with the 15mg dose over 72 weeks [4]. Importantly, the four-week intervals between dose increases allowed gastrointestinal adaptation, with discontinuation rates due to adverse events remaining below 6% across all dose groups.

The MHRA's approval of Mounjaro in the UK specifically references this dose escalation protocol, emphasising that the mounjaro dosage chart should be followed to maximise treatment success whilst maintaining patient safety. At Cured Pharmacy, our clinical team ensures all prescriptions align with these evidence-based guidelines, with treatment initiated only after thorough assessment by UK-registered prescribers.

Comparing Mounjaro Dosage to Other GLP-1 Treatments

The mounjaro dosage chart differs from other incretin-based therapies due to tirzepatide's dual GIP/GLP-1 receptor agonist mechanism. Whilst semaglutide (Wegovy) escalates from 0.25mg to 2.4mg over 16-20 weeks, Mounjaro's range extends to 15mg, reflecting different potency profiles and receptor binding characteristics [5]. The longer escalation period for Mounjaro—potentially up to 20 weeks to reach maximum dose—accommodates the dual agonist activity.

Liraglutide (Saxenda) uses daily injections with a simpler escalation from 0.6mg to 3.0mg over five weeks. The mounjaro dosage chart's weekly administration and extended titration schedule offer convenience advantages whilst the structured progression supports superior weight loss outcomes observed in head-to-head trials [2].

Mounjaro Dosage Chart for Special Populations

The standard mounjaro dosage chart requires modification for certain patient populations. Individuals with moderate renal impairment (eGFR 30-59 mL/min/1.73m²) can typically follow the standard escalation schedule, but those with severe renal impairment or end-stage renal disease have limited clinical data and require careful monitoring with potential dose capping at lower maintenance levels [3].

Elderly patients (aged 65 and above) may experience heightened sensitivity to gastrointestinal effects. While no formal dose adjustment is required based on age alone, our clinical team at Cured Pharmacy often recommends extended intervals between escalations—up to six weeks at each dose level—to optimise tolerability. The mounjaro dosage chart remains the foundation, but progression pace becomes more conservative.

Patients with hepatic impairment can generally follow the standard mounjaro dosage chart, as tirzepatide undergoes proteolytic cleavage rather than hepatic metabolism. However, those with significant cardiovascular disease may benefit from slower titration and closer monitoring during dose escalation. All prescription decisions at Cured Pharmacy are made by UK-registered prescribers following comprehensive clinical assessment, ensuring the mounjaro dosage chart application suits individual patient circumstances.

Practical Tips for Following Your Mounjaro Dosage Chart

Successfully adhering to the mounjaro dosage chart requires practical strategies. Mark your injection day on a calendar or set smartphone reminders to maintain the weekly schedule. Store pens in the refrigerator at 2-8°C until first use, then they may be kept at room temperature (not exceeding 30°C) for up to 21 days. Always check the pen cap colour matches your current dose level on the mounjaro dosage chart before injecting.

Keep a symptom diary during dose escalations, noting any gastrointestinal effects, changes in appetite, and weekly weight measurements. This information helps your prescriber determine optimal timing for progression through the mounjaro dosage chart. If side effects become troublesome, contact your healthcare provider before the next scheduled increase—remaining at your current dose longer is preferable to discontinuation.

Rotate injection sites systematically to prevent lipodystrophy and maintain consistent absorption. The mounjaro dosage chart's efficacy depends on reliable subcutaneous delivery, so proper injection technique is essential. Cured Pharmacy provides comprehensive patient information leaflets with every prescription, and our clinical team remains available on (+44) 116 4646009 to address any questions about following your personalised mounjaro dosage chart.

Managing Side Effects During Dose Escalation

Gastrointestinal effects are most common during the first few weeks after each dose increase on the mounjaro dosage chart. Nausea affects approximately 20-30% of patients but typically resolves within days as the body adjusts [4]. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce symptoms.

If side effects persist beyond two weeks at a new dose level, consult your prescriber before the next escalation. The mounjaro dosage chart allows flexibility—extending time at your current dose or even temporarily reducing to the previous level may be appropriate. Treatment success depends on finding your optimal maintenance dose, which may be lower than the maximum 15mg for many patients.

Accessing Mounjaro with a Personalised Dosage Chart

At Cured Pharmacy, obtaining Mounjaro following the appropriate mounjaro dosage chart begins with a free online clinical assessment taking under three minutes. Our UK-registered prescribers review your medical history, current medications, weight loss goals, and any contraindications to determine suitability for tirzepatide therapy. If approved, your prescription specifies the starting dose and escalation schedule tailored to your individual needs.

Mounjaro is available from £124.99 at Cured Pharmacy, with transparent pricing displayed before consultation. New patients can Save £20 using code Weightlossnew on their first order. We supply genuine UK-licensed Mounjaro KwikPens with complete patient information, including a personalised mounjaro dosage chart showing your specific escalation timeline. All medications are dispensed in 100% discreet packaging with next-day delivery options available.

Ongoing support throughout your treatment journey is included. As you progress through the mounjaro dosage chart, our clinical team monitors your response and adjusts the schedule if needed. Regular follow-up assessments ensure treatment remains safe, effective, and aligned with your weight loss objectives. Under the supervision of superintendent pharmacist Tarun Kumar (GPhC 2233073), Cured Pharmacy maintains the highest standards of pharmaceutical care whilst offering the most competitive UK pricing for Mounjaro.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 13 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.